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AbsTrACT
Objective To study the association between 
Dientamoebafragilis colonisation and faecal calprotectin 
to see whether the parasite is a harmless commensal or 
a gut pathogen.
Design Cross-sectional study of previously collected 
stool samples.
setting and patients Two hundred stool samples 
originated from children aged 5–19 years with chronic 
abdominal pain and diarrhoea, who were seen in 
paediatric clinics in the Netherlands and Belgium 
and in whom somatic gastrointestinal disorders were 
excluded. Another 122 samples came from a healthy 
community-based reference population of the same 
age. All stool samples were analysed with real-time 
PCR for the detection of D. fragilis and with an ELISA 
for calprotectin—a biomarker of gastrointestinal 
inflammation.
Main outcome measures Prevalence of D. fragilis 
colonisation and results of stool calprotectin testing.
results D. fragilis was detected in 45% (95% CI 
38% to 51%) of patients and in 71% (95% CI 63% to 
79%) of healthy children. Median (IQR) concentrations 
of calprotectin in patients and healthy children with a 
positive PCR result were not different from those with 
a negative PCR result (40 (40–55) μg/g vs 40 (40–75) 
μg/g, respectively).
Conclusion Since D. fragilis colonisation is most 
prevalent in healthy children and is not associated with 
an increase in faecal calprotectin concentration, our 
data do not support the inference that D. fragilis is a 
pathogenic parasite. Routinely testing for D. fragilis in 
children with chronic abdominal pain should therefore be 
discouraged.
InTrODuCTIOn
Dientamoeba fragilis, a flagellate protozoan parasite 
that inhabits the human bowel, was first described 
100 years ago by Jepps and Dobell, who thought of 
it as a non-pathogenic organism.1 Since then, many 
studies have assessed the pathogenicity of D. fragilis 
in two indirect ways. First, by linking its presence 
to gastrointestinal symptoms, including diarrhoea 
and abdominal pain, and second, by observing 
whether eradication leads to resolution of symp-
toms. In table 1, we present an overview of the clin-
ical studies that used these indirect methods from 
the year 2000 onwards. We show that, regardless of 
the method used, the controversy surrounding the 
pathogenicity of D. fragilis persists to this day.
A direct method to assess the pathogenicity of D. 
fragilis was used in mice, where inoculation with 
D. fragilis induced an influx of eosinophils, neutro-
phils and macrophages in the intestinal wall.2 If a 
similar inflammatory response would take place 
in the human gut, it should be possible to measure 
an increase of calprotectin in stool of colonised 
patients. Calprotectin is a peptide mainly released 
by neutrophils and also by macrophages and mono-
cytes invading the gut mucosa during an inflamma-
tory response.3 To date, it has only been shown in 
a mouse model that D. fragilis is associated with 
an elevated faecal calprotectin concentration.4 
In humans, this has not yet been investigated. We 
aimed to study the relationship between D. fragilis 
colonisation and stool calprotectin measurements.
MeThODs
Design
This study was a retrospectively planned secondary 
analysis of prospectively collected data. We used 
stool samples from a community-based cohort of 
healthy children (‘controls’) aged 5–19 years5 and 
from children with chronic abdominal pain and 
diarrhoea (‘cases’) aged 6–18 years.6
What is already known on this topic?
 ► The debate about the pathogenicity of 
Dientamoeba fragilis is ongoing.
 ► Previous studies tried to link the detection 
of the parasite in stool to the presence of 
gastrointestinal symptoms or observed whether 
successful eradication led to resolution of 
symptoms.
 ► Faecal calprotectin is a sensitive marker of 
intestinal inflammation.
What this study adds?
 ► We assessed whether the presence of D. fragilis 
in stool was associated with increased faecal 
calprotectin concentration.
 ► The lack of association between D. fragilis 
colonisation and intestinal inflammation 
suggests that the parasite is a harmless 
commensal.
 ► Routinely testing for D. fragilis in children 
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setting and participants
Controls (n=122) were recruited from primary and secondary 
schools in the Netherlands between June 2015 and March 
2016. Participants defecated onto a stool collection sheet 
(FecesCatcher, TAG Hemi VOF, Zeijen, The Netherlands) held 
above their toilet and collected one stool sample in a screw 
top container. In this way, contamination by toilet water was 
impossible. Containers were sent to the hospital laboratory of 
the University Medical Center Groningen. All samples with a 
transport time exceeding 7 days were excluded, as stability of 
calprotectin was no longer guaranteed.3 On arrival, samples 
were stored at −80°C until further analysis. Detailed inclusion 
and exclusion criteria are listed in the published study protocol.5
Cases had persistent diarrhoea for more than 4 weeks, or 
more than two episodes of abdominal pain and diarrhoea in 
the past 6 months, and consulted a paediatrician for the first 
time for this complaint. They were recruited from 3 tertiary 
care and 16 secondary care centres in both the Netherlands 
and Belgium.6 Stool samples were collected between September 
2014 and September 2016. The collection method, transport 
time and storage were similar as described for the controls. For 
the purpose of this study, we excluded stool samples from cases 
who were eventually diagnosed with a somatic gastrointestinal 
disorder or gastrointestinal infection other than D. fragilis and 
remained with 200 stool samples for the current study.
Measurements
We used real-time PCR to determine the presence of D. fragilis. 
Additionally, faecal samples from cases were also tested for other 
gastrointestinal pathogens, including Shiga toxin-producing 
Escherichia coli, E. coli O157gen, Cryptosporidium, Entamoeba 
histolytica, Giardia lamblia, Salmonella, Shigella/enteroinvasive 
E. coli and Campylobacter.7 Calprotectin concentrations were 
measured with the fCal ELISA test of BÜHLMANN Laborato-
ries AG (Schönenbuch, Switzerland).
Variables
Primary outcome of this study was the distribution of stool 
calprotectin concentrations in individuals colonised with D. 
fragilis compared with the distribution in those without the 
parasite.
statistical methods
Demographic information and stool results were recorded elec-
tronically using SPSS V.22.0 for Windows and are presented with 
GraphPad Prism V.7 for Mac (GraphPad Software, San Diego, 
California, USA). Standard descriptive statistics were used. Not 
normally distributed variables are presented as median and IQR 
and were tested using the Mann-Whitney U test. All tests were 
two sided, and the level of significance was set at a p value <0.05.
ethical approval
The data were collected and recorded by the investigators in such 
a manner that subjects could not be identified, neither directly 
nor through identifiers linked to the subjects. The legal guard-
ians from all participants, as well as the children aged 12 years 
and above, gave informed consent to use residual materials for 
future research.
Table 1 Studies on the pathogenicity of Dientamoeba fragilis. Excluding case studies and studies published before the year 2000
study
research question Considers Dientamoeba to be
Detection method
Is the presence of GI symptoms 
linked to positive stool tests?
Does eradication lead to 
resolution of symptoms? Pathogenic not pathogenic
de Wit de et al17 ✓ ✓ LM
Bosman et al18 ✓ ✓ TFT
Stark et al19 ✓ ✓ PCR
Vandenberg et al20 ✓ ✓ PCR and TFT
Kurt et al21 ✓ ✓ LM
Stark et al22 ✓ ✓ ✓ PCR
Yakoob et al23 ✓ ✓ PCR and LM
Engsbro et al24 ✓ ✓ PCR
de Jong et al12 ✓ ✓ ✓ PCR
Röser et al25 ✓ ✓ PCR
Bruijnesteijn van Coppenraet et al13 ✓ ✓ PCR
Krogsgaard et al11 ✓ ✓ PCR and LM
Ögren et al26 ✓ ✓ PCR and LM
Holtman et al14 ✓ ✓ PCR
Jokelainen et al15 ✓ ✓ PCR
GI, gastrointestinal; LM, light microscopy; TFT, triple faeces test.
Figure 1 Point estimate (and 95% CI) of Dientamoeba fragilis 









is Child: first published as 10.1136/archdischild-2018-316383 on 23 February 2019. Downloaded from
 
3Brands MR, et al. Arch Dis Child 2019;0:1–4. doi:10.1136/archdischild-2018-316383
Original article
resulTs
We analysed stool samples from 122 controls (48% men) with a 
median (IQR) age of 12 (9–14) years, and from 200 cases (52% 
men) with a median (IQR) age of 12 (9–15) years. Gender and 
age distribution were not different between groups (p=0.491 and 
0.154, respectively).
Prevalence
Figure 1 shows that 87 of 122 controls (71%, 95% CI 63% 
to 79%) were colonised with D. fragilis, compared with 89 of 
200 cases (45%, 95% CI 38% to 51%). The difference between 
groups was significant (p<0.001).
Figure 2 shows a decreasing prevalence of D. fragilis coloni-
sation with increasing age during childhood and adolescence. 
When using 5 year intervals in age (5 to 9, 10 to 14, and 15 to 
19 years), D. fragilis prevalence was respectively 67% (95%CI 
57 to 76), 59% (95%CI 51 to 67) and 31% (95%CI 22 to 42).
Faecal calprotectin
Six of 322 frozen samples contained too little faecal material 
to measure the calprotectin concentration. The remaining 316 
samples were further analysed. One hundred and seventy samples 
(54%, 95% CI 48% to 59%) tested positive for D. fragilis. The 
median (IQR) calprotectin concentration in these samples was 
40 (40–55) µg/g, compared with 40 (40–75) μg/g in the D. fragi-
lis-negative samples, as shown in figure 3.
DIsCussIOn
In this paper, we present for the first time that D. fragilis coloni-
sation in children and teenagers is not associated with increased 
faecal calprotectin concentrations. In combination with the 
observation that D. fragilis colonisation is most prevalent in 
healthy individuals, we postulate that the parasite is a non-patho-
genic organism. Presence of the parasite does not trigger inflam-
matory cells to release calprotectin.
Comparison with existing literature
As far as we know, no other faecal markers of intestinal inflam-
mation have yet been investigated on their association with D. 
fragilis. We identified one animal study that investigated the rela-
tionship between the presence of D. fragilis and faecal calpro-
tectin in mice.4 The group of mice that were inoculated with D. 
fragilis had a mean (SD) faecal calprotectin concentration of 69 
(22) ng/mL, compared with 33 (13) ng/mL in control mice. The 
small sample size (n=16) and the questionable applicability of 
this animal model to study human dientamoebiasis reduce the 
relevance of these observations.
Despite the use of the stool collection sheet to prevent the 
contamination of stool samples with toilet water, the prevalence 
of D. fragilis colonisation in the controls is among the highest 
currently reported. A literature search indicated that the preva-
lence of D. fragilis varied from 0.4% in healthy school children 
from Turkey8 to 61% in healthy school children from Lebanon.9 
Higher prevalences can be partially ascribed to the use of real-
time PCR, which is more sensitive than light microscopy.7 
Furthermore, higher rates of D. fragilis colonisation are often 
seen where sanitation and hygiene levels are poor.10 Perhaps the 
high prevalence of D. fragilis colonisation is a reflection of the 
waning habit of hand washing before meals in the Netherlands.
The observation that D. fragilis is more commonly detected 
in healthy, non-symptomatic individuals than in symptomatic 
patients was previously done by numerous other adult and paedi-
atric case–control studies.11–15 All of these studies questioned the 
pathogenicity of D. fragilis (see table 1).
Implications for paediatric practice
The availability of testing for D. fragilis, as part of the routine 
evaluation of children with gastrointestinal symptoms, varies 
between different European countries. We recently sent out a 
survey in the form of a clinical problem-solving exercise16 to 
assess the current practice in the Netherlands and Belgium in 
relation to D. fragilis. The 30 respondents came from paediatric 
centres involved in the recruitment of cases for the current study. 
We observed that there was no uniformity in the detection of 
D. fragilis nor in the management of D. fragilis positive chil-
dren with chronic abdominal pain and diarrhoea. The approach 
varied from ignoring the presence of the parasite to making an 
effort to eradicate.
The findings of the current study add to the ongoing debate 
about the pathogenicity of D. fragilis. Detection of the para-
site in stool is not associated with increased faecal calprotectin 
Figure 2 Point estimate (and 95% CI) of Dientamoeba fragilis 
prevalence per age category.
Figure 3 Dot plot of faecal calprotectin concentrations in children 
with and without Dientamoeba fragilis colonisation. The top whisker 
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concentrations, and we therefore postulate that the parasite is 
merely a harmless commensal.
We acknowledge that stool calprotectin testing is an indi-
rect method to evaluate neutrophil invasion of the gut mucosa. 
However, our observations that D. fragilis colonisation is: 
(1) not associated with increased faecal calprotectin concentra-
tions and (2) most prevalent in healthy individuals do not justify 
invasive procedures such as taking mucosal biopsies to further 
investigate its pathogenicity. We advise against testing for D. 
fragilis in children with chronic abdominal pain.
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